Sun Pharmaceutical Industries, India's largest drugmaker by market value, has signed a definitive agreement to acquire Organon, a global healthcare company, for $11.75 billion. The deal marks one of the largest acquisitions in the Indian pharmaceutical sector.
Details of the Acquisition
Organon is a global healthcare company that was formed through a spinoff from Merck, known as MSD outside of the United States and Canada, in 2021. The company focuses on women's health, biosimilars, and established medicines. The acquisition is expected to strengthen Sun Pharma's portfolio in these therapeutic areas.
Strategic Rationale
The acquisition will significantly expand Sun Pharma's presence in the global market, particularly in women's health and biosimilars. It will also provide access to Organon's established commercial infrastructure in key international markets.
Sun Pharma's Chairman, Dilip Shanghvi, stated that the deal aligns with the company's strategy to build a diversified global business. The transaction is expected to close by the end of 2026, subject to regulatory approvals.
Financial Details
The $11.75 billion deal will be financed through a combination of cash, debt, and equity. Sun Pharma has secured financing commitments from leading banks. The company expects the acquisition to be accretive to earnings per share from the first year post-closure.
Market Reaction
Shares of Sun Pharma rose by 3.5% on the Bombay Stock Exchange following the announcement. Analysts have largely welcomed the deal, citing strategic benefits and potential synergies. However, some have expressed concerns about the debt burden that Sun Pharma will take on.
The acquisition is expected to create a combined entity with annual revenues exceeding $10 billion, making Sun Pharma one of the top 20 pharmaceutical companies globally.
